Duloxetin Actavis (Duloxetine)
Serotonin-norepinephrine reuptake inhibitor (SNRI) for stress urinary incontinence
Quick Facts: Duloxetin Actavis
Key Takeaways
- Duloxetin Actavis is a duloxetine-based SNRI medication specifically indicated for stress urinary incontinence in women, taken as 40 mg twice daily.
- It must not be combined with MAO inhibitors, fluvoxamine, ciprofloxacin, or enoxacin due to serious interaction risks.
- The most common side effects are nausea, dry mouth, constipation, and fatigue — typically mild and often resolving within a few weeks.
- Treatment should never be stopped abruptly; your doctor will taper the dose over at least two weeks to prevent withdrawal symptoms.
- Best results are achieved when duloxetine treatment is combined with pelvic floor muscle training exercises.
What Is Duloxetin Actavis and What Is It Used For?
Quick Answer: Duloxetin Actavis contains duloxetine, an SNRI that increases serotonin and norepinephrine in the nervous system. It is prescribed for stress urinary incontinence (SUI) in women — reducing involuntary urine leakage during physical activity.
Duloxetin Actavis belongs to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs). The active substance, duloxetine, works by blocking the reuptake of two key neurotransmitters — serotonin and norepinephrine — in the central nervous system. This dual mechanism of action strengthens the neural control of the urethral sphincter, the muscle responsible for holding urine in the bladder.
Stress urinary incontinence (SUI) is a common medical condition affecting millions of women worldwide, particularly after childbirth, during menopause, or as a result of pelvic floor muscle weakness. SUI causes involuntary urine leakage during activities that increase abdominal pressure, such as coughing, sneezing, laughing, heavy lifting, or vigorous exercise. It is not related to emotional or psychological stress, despite the name.
In the context of SUI, duloxetine acts specifically at the level of the sacral spinal cord, in an area called Onuf's nucleus. By increasing serotonin and norepinephrine activity in this region, duloxetine enhances the contraction of the urethral striated sphincter during the urine storage phase. This results in stronger closure of the urethra when physical stress is applied to the bladder, thereby reducing episodes of leakage.
Clinical trials have demonstrated that duloxetine significantly reduces the number of incontinence episodes compared to placebo, and the therapeutic effect is further enhanced when medication is combined with a structured pelvic floor muscle training program. The combination of duloxetine and physical therapy offers a synergistic approach that addresses both the neurological and muscular components of continence.
It is important to note that duloxetine as a pharmaceutical substance is also approved under different brand names for the treatment of major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia. However, Duloxetin Actavis in this formulation is specifically indicated for stress urinary incontinence. You should not use multiple duloxetine-containing products simultaneously.
What Should You Know Before Taking Duloxetin Actavis?
Quick Answer: Duloxetin Actavis is contraindicated in patients with liver disease, severe kidney disease, or those taking MAO inhibitors. Special caution is needed for patients with high blood pressure, heart disease, glaucoma, bleeding disorders, or a history of seizures.
Contraindications
There are several situations in which you must not take Duloxetin Actavis. Understanding these contraindications is critical for your safety. Do not take this medicine if you:
- Are allergic to duloxetine or any of the other ingredients in the capsules (see the Ingredients section below for a full list of excipients).
- Have liver disease — duloxetine is extensively metabolized by the liver, and hepatic impairment significantly increases drug exposure and the risk of liver injury.
- Have severe kidney disease — renal impairment (creatinine clearance below 30 mL/min) significantly affects drug elimination.
- Are taking or have recently taken (within the last 14 days) a monoamine oxidase inhibitor (MAO inhibitor) such as moclobemide, phenelzine, tranylcypromine, or linezolid. The combination can cause serotonin syndrome, a potentially life-threatening condition.
- Are taking fluvoxamine (an SSRI commonly used for depression or OCD), ciprofloxacin, or enoxacin (antibiotics) — these drugs potently inhibit the CYP1A2 enzyme that metabolizes duloxetine, leading to dangerously elevated blood levels.
Additionally, speak with your doctor before starting treatment if you have high blood pressure or heart disease. Your doctor will determine whether Duloxetin Actavis is appropriate for your specific medical situation.
Warnings and Precautions
Even if you do not have the contraindications listed above, Duloxetin Actavis may not be suitable for everyone. Discuss the following with your doctor before starting treatment:
- Other antidepressant medications: Concurrent use of other serotonergic medicines (SSRIs, SNRIs, tricyclics) increases the risk of serotonin syndrome.
- St John's Wort (Hypericum perforatum): This herbal supplement has serotonergic properties and should not be combined with duloxetine.
- Kidney disease: Even mild to moderate renal impairment may require dose adjustments or additional monitoring.
- History of seizures: Duloxetine may lower the seizure threshold; caution is required in patients with epilepsy or a history of convulsions.
- Bipolar disorder or mania: SNRI medications may trigger manic episodes in susceptible individuals.
- Glaucoma: Duloxetine may increase intraocular pressure, particularly in narrow-angle glaucoma. Report any eye pain, visual changes, or swelling/redness in or around the eye immediately.
- Bleeding disorders: Duloxetine affects serotonin, which plays a role in platelet aggregation. There is an increased risk of bruising and bleeding, especially when combined with anticoagulants or NSAIDs.
- Low sodium (hyponatremia): Risk is elevated in elderly patients and those taking diuretics. Symptoms include dizziness, weakness, confusion, and drowsiness.
- Liver-damaging medications: Co-administration with other hepatotoxic drugs requires additional monitoring of liver function.
Contact your doctor immediately if you experience a combination of: restlessness, hallucinations, loss of coordination, rapid heartbeat, increased body temperature, rapid blood pressure changes, overactive reflexes, diarrhoea, nausea, or vomiting. These may be signs of serotonin syndrome, which in its most severe form can resemble neuroleptic malignant syndrome (NMS) — characterized by fever, rapid heartbeat, sweating, severe muscle rigidity, and confusion.
Medications like Duloxetin Actavis (SSRIs/SNRIs) may cause symptoms of sexual dysfunction, including decreased libido, difficulty achieving orgasm, or erectile dysfunction. In some cases, these symptoms have persisted after discontinuation of treatment. Discuss any concerns with your doctor.
Suicidal Thoughts and Behaviour
Although Duloxetin Actavis is not indicated for the treatment of depression, the active substance duloxetine is also used as an antidepressant. Patients who are depressed or have anxiety may sometimes experience thoughts of self-harm or suicide. These symptoms may worsen at the start of treatment, as it typically takes about two weeks before the medication reaches its full effect.
You may be more likely to have such thoughts if you have previously had thoughts of self-harm or suicide, or if you are under 25 years of age. Studies have shown that young adults (under 25) with psychiatric conditions who are treated with antidepressants have an increased risk of suicidal thoughts and self-harm behaviour. If you experience any thoughts of self-harm, contact your doctor or go to a hospital immediately.
Children and Adolescents
Duloxetin Actavis must not be used in children and adolescents under 18 years of age. In this age group, the risk of side effects such as suicidal behaviour, self-harm thoughts, and hostility (including aggression, defiance, and anger) is greater. Furthermore, the long-term effects on growth, maturation, and cognitive and behavioural development have not been established in this population.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant, or are planning to become pregnant, consult your doctor before using Duloxetin Actavis. You should only use this medicine during pregnancy after careful evaluation of the potential benefits against the risks to the unborn child.
When similar medications (SSRIs/SNRIs) are used during pregnancy, there may be an increased risk of a serious condition called persistent pulmonary hypertension of the newborn (PPHN). This condition causes the baby to breathe faster and appear bluish, typically within 24 hours of birth. If this occurs, seek immediate medical attention.
If Duloxetin Actavis is taken during late pregnancy, the newborn may experience symptoms such as limp muscles, tremor, feeding difficulties, breathing problems, and seizures. There is also an increased risk of preterm delivery (approximately 6 extra preterm births per 100 women taking duloxetine in the second half of pregnancy, mostly between weeks 35 and 36) and an increased risk of heavy vaginal bleeding shortly after delivery, particularly if you have a history of bleeding disorders.
Available data from the first trimester of pregnancy do not suggest an overall increased risk of birth defects. However, the decision to use duloxetine during pregnancy must be made on an individual basis by your doctor.
Breastfeeding is not recommended during treatment with Duloxetin Actavis, as duloxetine passes into breast milk. Consult your doctor for guidance on alternative options.
Driving and Operating Machinery
Duloxetin Actavis may cause drowsiness and dizziness. Do not drive or operate heavy machinery until you know how this medicine affects you. It is your responsibility to assess whether you are fit to drive or perform work requiring alertness.
How Does Duloxetin Actavis Interact with Other Drugs?
Quick Answer: Duloxetin Actavis has clinically significant interactions with MAO inhibitors, certain antibiotics (ciprofloxacin, enoxacin), fluvoxamine, serotonergic drugs, and anticoagulants. Always inform your doctor of all medications you are taking, including over-the-counter products and herbal supplements.
Drug interactions with Duloxetin Actavis can be broadly categorized as pharmacokinetic (affecting how the drug is metabolized) and pharmacodynamic (affecting how the drug works). The most dangerous interactions involve drugs that either greatly increase duloxetine levels in the blood or those that amplify its serotonergic effects.
Duloxetine is primarily metabolized by the liver enzymes CYP1A2 and CYP2D6. Strong inhibitors of CYP1A2 — such as fluvoxamine, ciprofloxacin, and enoxacin — can increase duloxetine plasma concentrations by several-fold, substantially raising the risk of dose-dependent side effects. Conversely, potent CYP1A2 inducers (e.g., smoking) may decrease duloxetine levels and reduce its effectiveness.
Major Interactions (Avoid Completely)
| Drug / Class | Risk | Action Required |
|---|---|---|
| MAO Inhibitors (moclobemide, phenelzine, linezolid) | Serotonin syndrome — potentially fatal | Wait 14 days after stopping MAO inhibitor before starting duloxetine. Wait 5 days after stopping duloxetine before starting MAO inhibitor. |
| Fluvoxamine | Strong CYP1A2 inhibition — massively increased duloxetine levels | Combination is contraindicated. Do not use together. |
| Ciprofloxacin | Strong CYP1A2 inhibition — elevated duloxetine levels | Combination is contraindicated. Use alternative antibiotic. |
| Enoxacin | Strong CYP1A2 inhibition — elevated duloxetine levels | Combination is contraindicated. Use alternative antibiotic. |
Interactions Requiring Caution
| Drug / Class | Risk | Recommendation |
|---|---|---|
| SSRIs (paroxetine, fluoxetine, sertraline) | Increased serotonin syndrome risk; CYP2D6 inhibition | Avoid combination if possible. Monitor closely for serotonergic symptoms. |
| Triptans (sumatriptan, rizatriptan) | Increased serotonin syndrome risk | Use with caution. Monitor symptoms after each dose. |
| Tramadol, Buprenorphine, Pethidine | Serotonin syndrome; reduced seizure threshold | Use lowest effective dose. Consider alternative analgesics. |
| Tricyclic antidepressants (amitriptyline, clomipramine) | Serotonin syndrome; CYP2D6 interaction increases TCA levels | Avoid combination. If necessary, use reduced TCA dose with monitoring. |
| St John's Wort (Hypericum perforatum) | Increased serotonergic effects | Do not combine. Discontinue herbal supplement before starting treatment. |
| Anticoagulants / Antiplatelets (warfarin, aspirin, clopidogrel) | Increased bleeding risk | Monitor for signs of bleeding. INR monitoring if on warfarin. |
| Benzodiazepines, Strong Opioids, Antipsychotics | Enhanced sedation and drowsiness | Caution with driving. Consider dose reduction of sedating drugs. |
| Tryptophan | Increased serotonergic activity | Avoid concurrent use with high-dose tryptophan supplements. |
You should exercise caution with alcohol consumption while taking Duloxetin Actavis. Alcohol can increase the risk of liver damage and may enhance the sedative effects of the medication, leading to increased drowsiness and impaired coordination.
The active ingredient duloxetine is also used in other medications for conditions such as depression, anxiety, and diabetic neuropathic pain. You must never take more than one duloxetine-containing product at the same time. Always inform your healthcare provider about all medicines you are using.
What Is the Correct Dosage of Duloxetin Actavis?
Quick Answer: The standard adult dose is 40 mg twice daily (morning and evening). Treatment may be started at 20 mg twice daily for two weeks before increasing. Always follow your doctor's instructions — do not change the dose without medical guidance.
Duloxetin Actavis should always be taken exactly as prescribed by your doctor. The capsules are swallowed whole with a glass of water and may be taken with or without food. Taking the medication at the same time each day helps maintain consistent blood levels and makes it easier to remember your doses.
Adults
Standard Dose
40 mg twice daily (one capsule in the morning and one in the late afternoon or evening), giving a total daily dose of 80 mg. Your doctor may start you on a lower dose of 20 mg twice daily for the first two weeks to improve tolerability, then increase to the full dose of 40 mg twice daily.
Clinical studies have shown that most patients begin to notice improvement within 2 to 4 weeks of treatment at the full dose. The medication works best when combined with pelvic floor muscle exercises (also known as Kegel exercises), which strengthen the muscles that support the bladder and urethra. Your doctor or physiotherapist can provide guidance on an appropriate exercise program.
Children and Adolescents
Under 18 Years
Duloxetin Actavis is not recommended for children and adolescents under 18 years of age. Safety and efficacy have not been established in this age group, and there is an increased risk of serious side effects including suicidal behaviour.
Elderly Patients
Over 65 Years
No routine dose adjustment is required solely based on age. However, elderly patients may be more susceptible to certain side effects, particularly low sodium levels (hyponatremia) and dizziness/falls. Your doctor may start at a lower dose and monitor you more closely.
Missed Dose
If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and take only your regular dose. Do not take a double dose to make up for the one you missed. Never take more Duloxetin Actavis per day than your doctor has prescribed.
Overdose
If you take more Duloxetin Actavis than prescribed, or if a child accidentally ingests the medicine, contact your doctor, emergency services, or a poison control centre immediately. Symptoms of overdose may include drowsiness, coma, serotonin syndrome, seizures, vomiting, and rapid heartbeat. Prompt medical treatment is essential.
What Happens When You Stop Taking Duloxetin Actavis?
Quick Answer: Never stop Duloxetin Actavis abruptly. Your doctor will gradually reduce the dose over at least two weeks. Abrupt discontinuation can cause withdrawal symptoms including dizziness, electric shock sensations, nausea, insomnia, and anxiety.
It is critically important that you do not stop taking Duloxetin Actavis suddenly, even if you feel better. Abrupt discontinuation after more than one week of treatment may cause a range of withdrawal symptoms known as discontinuation syndrome. These symptoms include:
- Dizziness and vertigo
- Tingling sensations or electric shock-like feelings (particularly in the head), often described as "brain zaps"
- Sleep disturbances including vivid dreams, nightmares, and insomnia
- Fatigue, drowsiness, and restlessness
- Anxiety and agitation
- Nausea, vomiting, and diarrhoea
- Tremor, headache, and muscle pain
- Irritability and excessive sweating
When your doctor decides that you no longer need Duloxetin Actavis, they will typically reduce the dose gradually over at least two weeks. This tapering approach significantly reduces the incidence and severity of discontinuation symptoms. If you experience troublesome symptoms during dose reduction, consult your doctor — a more gradual taper may be needed.
What Are the Side Effects of Duloxetin Actavis?
Quick Answer: Like all medicines, Duloxetin Actavis can cause side effects, although not everyone gets them. The most common are nausea, dry mouth, constipation, and fatigue. Most side effects are mild to moderate and tend to resolve within the first few weeks of treatment.
Side effects of duloxetine are well-characterised from extensive clinical trials and post-marketing surveillance. They are categorised below according to their frequency of occurrence, based on data from the European Medicines Agency (EMA) and clinical trial databases.
Very Common
May affect more than 1 in 10 people
- Nausea
- Dry mouth
- Constipation
- Fatigue
Common
May affect up to 1 in 10 people
- Decreased appetite
- Insomnia, agitation, decreased libido, anxiety
- Headache, dizziness, feeling sluggish, drowsiness, tremor, numbness or tingling
- Blurred vision
- Vertigo
- Elevated blood pressure, flushing
- Diarrhoea, abdominal pain, heartburn, indigestion
- Increased sweating
- Weakness, chills
Uncommon
May affect up to 1 in 100 people
- Throat inflammation causing hoarse voice
- Allergic reactions, decreased thyroid function
- Dehydration, teeth grinding, disorientation, lack of motivation
- Difficulty achieving orgasm, unusual dreams, nervousness, difficulty concentrating
- Dilated pupils, dry eyes, tinnitus, ear pain
- Palpitations, rapid or irregular heartbeat
- Fainting, yawning
- Bloody vomit or black tarry stools, mouth inflammation, difficulty swallowing
- Liver inflammation (hepatitis), rash, hives, night sweats, easy bruising
- Muscle pain, muscle tension, jaw muscle spasms
- Difficulty starting urination, painful urination, frequent urination
- Abnormal vaginal bleeding, menopausal symptoms
- Chest pain, feeling cold, thirst, weight changes
- Elevated liver enzymes, blood cholesterol, or blood sugar
Rare / Very Rare
May affect up to 1 in 1,000 people (or fewer)
- Severe allergic reactions (anaphylaxis) with breathing difficulties, swollen tongue/lips
- Low sodium levels (SIADH) — symptoms include confusion, drowsiness, seizures
- Suicidal thoughts or behaviour, mania, aggression
- Serotonin syndrome, seizures, involuntary muscle movements, restless legs
- Increased eye pressure (glaucoma)
- Fainting on standing (orthostatic hypotension), cold extremities
- Throat tightness, nosebleed, wheezing
- Liver problems, jaundice (yellowing of skin/eyes)
- Stevens-Johnson syndrome, angioedema, photosensitivity
- Urinary retention, galactorrhoea (abnormal breast milk production)
- Postpartum haemorrhage (heavy vaginal bleeding after delivery)
- Stress cardiomyopathy (chest pain, breathlessness, irregular heartbeat)
- Cutaneous vasculitis (inflammation of skin blood vessels)
If you experience any side effects, including any not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority. By reporting side effects, you help provide more information on the safety of this medicine.
How Should You Store Duloxetin Actavis?
Quick Answer: Store below 25°C, in the original packaging, out of the reach of children. Do not use after the expiry date. Do not dispose of medicines via wastewater or household waste — ask your pharmacist for proper disposal methods.
Proper storage of medications is essential to ensure they remain effective and safe throughout their shelf life. Store Duloxetin Actavis at a temperature not exceeding 25°C (77°F). Keep the capsules in their original packaging to protect them from moisture, and store them out of the sight and reach of children.
Do not use this medicine after the expiry date printed on the carton after "EXP." The expiry date refers to the last day of that month. If you notice any change in the appearance of the capsules, or if the packaging is damaged, do not use the medicine and consult your pharmacist.
When you no longer need the medicine or it has expired, do not throw it away in household waste or flush it down the drain. Return unused medication to your pharmacy, where it will be disposed of in an environmentally responsible manner. These measures help protect the environment from pharmaceutical contamination.
What Does Duloxetin Actavis Contain?
Quick Answer: Each capsule contains either 20 mg or 40 mg of duloxetine (as hydrochloride). Inactive ingredients include sugar spheres, hypromellose phthalate, triethyl citrate, and talc. The capsule shell uses hypromellose (HPMC) with colouring agents.
Active Ingredient
Each capsule contains duloxetine (as duloxetine hydrochloride) in one of two strengths: 20 mg or 40 mg.
Inactive Ingredients (Excipients)
Capsule contents: Sugar spheres (sucrose, maize starch), hypromellose phthalate, hypromellose (E15 LV), triethyl citrate, hydroxypropylcellulose, and talc.
20 mg capsule shell: Brilliant blue FCF (E133), titanium dioxide (E171), hypromellose (E464). Opaque blue capsule marked "DLX 20" on both halves, length 15.9 mm.
40 mg capsule shell: Titanium dioxide (E171), yellow iron oxide (E172), hypromellose (E464). Opaque yellow capsule marked "DLX 40" on both halves, length 19.4 mm.
Printing ink: Shellac, propylene glycol, black iron oxide (E172), potassium hydroxide.
Duloxetin Actavis capsules contain sugar spheres made with sucrose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Packaging
Duloxetin Actavis is available in HDPE plastic bottles with screw caps (containing silica gel desiccant) in pack sizes of 28, 30, 56, 60, 84, 90, 98, and 100 capsules. It is also available in PVC/PVDC/PVC/aluminium blister packs in pack sizes of 7, 10, 28, 30, 56, and 100 capsules. Not all pack sizes may be marketed in your country.
Frequently Asked Questions About Duloxetin Actavis
References
This article is based on the following international medical sources and peer-reviewed evidence. All medical claims have evidence level 1A, the highest quality of evidence based on systematic reviews and randomized controlled trials.
- European Medicines Agency (EMA). Duloxetine — Summary of Product Characteristics. EMA Product Information. Available at: www.ema.europa.eu
- Mariappan P, Ballantyne Z, N'Dow JM, Glazener CM. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database of Systematic Reviews. 2005;(3):CD004742. doi:10.1002/14651858.CD004742.pub2
- Cardozo L, Drutz HP, Baygani SK, Bump RC. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstetrics & Gynecology. 2004;104(3):511-519.
- Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU International. 2004;93(3):311-318.
- Norton PA, Zinner NR, Yalcin I, Bump RC; Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of stress urinary incontinence. American Journal of Obstetrics and Gynecology. 2002;187(1):40-48.
- British National Formulary (BNF). Duloxetine — Urinary Incontinence. NICE BNF. Available at: bnf.nice.org.uk
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023.
- U.S. Food and Drug Administration (FDA). Cymbalta (duloxetine hydrochloride) — Prescribing Information. Available at: www.accessdata.fda.gov
- Bauer M, Pfennig A, Severus E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. World Journal of Biological Psychiatry. 2013;14(5):334-385.
- Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. Journal of Urology. 2003;170(4 Pt 1):1259-1263.
About the Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in clinical pharmacology, urology/urogynaecology, and internal medicine. Our team follows international editorial guidelines and the GRADE evidence framework to ensure the highest standard of medical accuracy.
Medical Content
Written by licensed clinical pharmacologists with expertise in drug safety, pharmacokinetics, and evidence-based pharmacotherapy.
Medical Review
Independently reviewed by the iMedic Medical Review Board in accordance with EMA, FDA, and WHO guidelines.
Editorial Standards: Evidence Level 1A | GRADE Framework | No commercial funding | Independent medical editorial content | Last reviewed: